A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Trial Profile

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Gemcitabine (Primary) ; LY 3023414 (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-238
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
    • 04 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 May 2018.
    • 12 Sep 2017 Results (n=29, Data cut off: 1 Mar 2017) of cohort D (Abema [100, 150 mg, or 200 mg] was given orally on a continuous schedule every 12 hours (q12h) with LY at 100, 150, or 200 mg q12h) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top